Pharma Mar S A : Share buy-back, stabilization and treasury stock programs

September 23, 2020 at 11:50 am EDT

National Securities Market Commission Markets Directorate General

C/ Edison núm. 4 28006 Madrid

Colmenar Viejo (Madrid), 23 September 2020

In accordance with article 227 of the recast Spanish Securities Market Act (Ley del Mercado de Valores), approved by Royal Legislative Decree 4/2015 of 23 October, articles 2.2 and 2.3 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programs and stabilisation measures and concordant provisions, is hereby reported the following

OTHER RELEVANT INFORMATION

Share buy-back, stabilization and treasury stock programs

In relation to the program to buy-back treasury shares announced by means of inside information communication dated March 25, 2020 (registration number 113) (the "Buy-backProgram"), Pharma Mar, S.A. (the "Company") hereby informs on the transactions carried out under the Buy-back Program during the period between September 16th and September 22th of 2020 (the "Period").

Date

Security

Transaction

Stock Exchange

Number of

Average Price

(€)

16/09/2020

PHM

Purchase

XMAD

8.204

99,65224

17/09/2020

PHM

Purchase

XMAD

5.000

99,22000

18/09/2020

PHM

Purchase

XMAD

4.681

101,60000

21/09/2020

PHM

Purchase

XMAD

20.292

99,10593

22/09/2020

PHM

Purchase

XMAD

8.000

98,46250

Detailed information on each of the transactions carried out by the Company during the Period is attached as an annex.

Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina

28770 Colmenar Viejo (Madrid) Spain www.pharmamar.com

ANNEX

Detailed information on treasury shares' acquisitions carried out during the Period

Date

Security

Transaction

Stock

Number of

Average

Broker

Exchange

Price (€)

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

211

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

150

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

200

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

146

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina

28770 Colmenar Viejo (Madrid) Spain www.pharmamar.com

Date

Security

Transaction

Stock

Number of

Average

Broker

Exchange

Price (€)

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

377

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

361

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

169

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

231

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

231

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

231

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

180

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

123

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

134

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

125

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

375

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

114

99,25000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

178

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

285

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

363

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

137

99,80000

JB Capital Markets, S.V. S.A.U

Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina

28770 Colmenar Viejo (Madrid) Spain www.pharmamar.com

Date

Security

Transaction

Stock

Number of

Average

Broker

Exchange

Price (€)

16/09/2020

PHM

Purchase

XMAD

143

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

148

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

168

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

230

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

300

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

100

99,80000

JB Capital Markets, S.V. S.A.U

16/09/2020

PHM

Purchase

XMAD

102

99,80000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

750

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

500

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

400

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

500

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

100

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

100

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

100

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

100

99,60000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

500

98,65000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

125

98,65000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

375

98,65000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

300

98,65000

JB Capital Markets, S.V. S.A.U

17/09/2020

PHM

Purchase

XMAD

98,65000

JB Capital Markets, S.V. S.A.U

Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina

28770 Colmenar Viejo (Madrid) Spain www.pharmamar.com

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original document
Permalink

Disclaimer

Pharma Mar SA published this content on 23 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2020 15:49:04 UTC

	1st Jan change	Capi.
PHARMA MAR, S.A.	-8.96%	712M
CSL LIMITED	-2.29%	89.38B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.92B
BIOGEN INC.	-13.07%	32.04B
UCB	+63.05%	26.03B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.14B
INCYTE CORPORATION	-7.96%	12.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.77B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.85B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	8.92B

1st Jan change

Capi.

PHARMA MAR, S.A.

-8.96%

712M

CSL LIMITED

-2.29%

89.38B

SAMSUNG BIOLOGICS CO.,LTD.

-3.95%

37.92B

BIOGEN INC.

-13.07%

32.04B

UCB

+63.05%

26.03B

BIOMARIN PHARMACEUTICAL INC.

-22.14%

14.14B

INCYTE CORPORATION

-7.96%

12.88B

BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.

-9.33%

11.77B

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

-46.33%

10.85B

SWEDISH ORPHAN BIOVITRUM AB

+5.77%

8.92B

Market Closed - BME Other stock markets 11:35:18 2024-05-31 am EDT			5-day change	1st Jan Change
37.4 ^EUR	+0.43%		+3.54%	-8.96%

Apr. 23	Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 29	Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024

Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024	Feb. 29
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Pharma Mar's Sylentis Meets Primary Endpoint for Dry Eye Disease Medication	Dec. 18	MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	Dec. 12	MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	Dec. 04	MT
Pharma Mar's Partner Wins Commercialization Approval for Zepzelca in Peru	Nov. 07	MT
PharmaMar Gets $10 Million Milestone Payment from Janssen Under Yondelis Licensing Deal	Nov. 06	MT
Transcript : Pharma Mar, S.A., Q3 2023 Earnings Call, Oct 27, 2023	23-10-27
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Pharma Mar, S.A. commences an Equity Buyback Plan, under the authorization approved on May 31, 2023.	23-09-05	CI
Transcript : Pharma Mar, S.A., H1 2023 Earnings Call, Jul 28, 2023	23-07-28
Pharma Mar, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-27	CI
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment	23-07-11	MT
Monetary optimism and Inditex drive the Ibex-35 to one-and-a-half month highs	23-06-07	RE
The Ibex rises cautiously as it waits for central banks to make their moves	23-06-06	RE
Pharma Mar Recruits First Patient for Solid Tumor Treatment Trial	23-05-04	MT
Transcript : Pharma Mar, S.A., Q1 2023 Earnings Call, Apr 27, 2023	23-04-27
Ibex-35 gives ground as it digests results, awaiting central banks	23-04-27	RE
Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Transcript : Pharma Mar, S.A., 2022 Earnings Call, Mar 01, 2023	23-03-01
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Pharma Mar Wins Conditional Approval For Lung Cancer Drug In Israel	23-01-31	MT
Spain's Pharma Mar Wins Approval for Lung Cancer Drug in Mexico	23-01-24	MT
Spain's Pharma Mar Kicks Off First-in-Human Study of Investigational Tumor Treatment	22-12-30	MT

Pharma Mar, S.A.

Equities

PHM

ES0169501022

Pharmaceuticals

Pharma Mar S A : Share buy-back, stabilization and treasury stock programs

Latest news about Pharma Mar, S.A.

Chart Pharma Mar, S.A.

Company Profile

Income Statement Evolution

Ratings for Pharma Mar, S.A.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals